25 September 2025
25 September 2025
As Eli Lilly and Novo Nordisk await approval of their oral GLP-1RAs, the healthcare editorial team discuss data and market opportunity.
A new FDA target action date of 28 December could bring tolebrutinib’s tumultuous development period to an end.
Biogen is one in a list of companies that have recently faced rejections due to CMC issues.
Sanofi Ventures is targeting early-stage and emerging opportunities in healthcare.
The contract replaces BARDA’s agreement with Venatorx, the company that licensed the oral antibiotic to Basilea.
The Dutch biotech will now file for AMT-130’s approval in Huntington’s disease.
Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s standing.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
